| Year |
Citation |
Score |
| 2024 |
Hui S, George J, Kapadia M, Chau H, Bariring Z, Earnshaw R, Shafiq K, Kalia LV, Kalia SK. Mitophagy Upregulation Occurs Early in the Neurodegenerative Process Mediated by α-Synuclein. Molecular Neurobiology. PMID 38581539 DOI: 10.1007/s12035-024-04131-6 |
0.344 |
|
| 2024 |
Lee EJ, Aguirre-Padilla DH, Fomenko A, Pawar G, Kapadia M, George J, Lozano AM, Hamani C, Kalia LV, Kalia SK. Reduction of alpha synuclein oligomers in preclinical models of Parkinson's disease by electrical stimulation in vitro and deep brain stimulation in vivo. Brain Stimulation. PMID 38342364 DOI: 10.1016/j.brs.2024.02.005 |
0.531 |
|
| 2023 |
Mestre TA, Kalia LV. α-synuclein seed amplification in Parkinson's disease. The Lancet. Neurology. 22: 984-985. PMID 37863603 DOI: 10.1016/S1474-4422(23)00374-5 |
0.325 |
|
| 2023 |
Nim S, O'Hara DM, Corbi-Verge C, Perez-Riba A, Fujisawa K, Kapadia M, Chau H, Albanese F, Pawar G, De Snoo ML, Ngana SG, Kim J, El-Agnaf OMA, Rennella E, Kay LE, ... ... Kalia LV, et al. Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease. Nature Communications. 14: 2150. PMID 37076542 DOI: 10.1038/s41467-023-37464-2 |
0.347 |
|
| 2021 |
Chen KS, Menezes K, Rodgers JB, O'Hara DM, Tran N, Fujisawa K, Ishikura S, Khodaei S, Chau H, Cranston A, Kapadia M, Pawar G, Ping S, Krizus A, Lacoste A, ... ... Kalia LV, et al. Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Molecular Neurodegeneration. 16: 77. PMID 34772429 DOI: 10.1186/s13024-021-00497-6 |
0.41 |
|
| 2021 |
Barbuti PA, Barker RA, Brundin P, Przedborski S, Papa SM, Kalia LV, Mochizuki H. Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33963552 DOI: 10.1002/mds.28628 |
0.32 |
|
| 2021 |
O'Hara DM, Kapadia M, Ping S, Kalia SK, Kalia LV. Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis. Journal of Visualized Experiments : Jove. PMID 33616088 DOI: 10.3791/62062 |
0.325 |
|
| 2020 |
Visanji NP, Madan P, Lacoste AMB, Buleje I, Han Y, Spangler S, Kalia LV, Alford SH, Marras C. Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease. Pharmacoepidemiology and Drug Safety. PMID 33219601 DOI: 10.1002/pds.5176 |
0.31 |
|
| 2020 |
Mylvaganam S, Earnshaw R, Heymann G, Kalia SK, Kalia LV. C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside. Current Neuropharmacology. PMID 33200713 DOI: 10.2174/1570159X18666201116145507 |
0.355 |
|
| 2020 |
Friesen EL, Zhang YT, Earnshaw R, De Snoo ML, O'Hara DM, Agapova V, Chau H, Ngana S, Chen KS, Kalia LV, Kalia SK. BAG5 Promotes Alpha-Synuclein Oligomer Formation and Functionally Interacts With the Autophagy Adaptor Protein p62. Frontiers in Cell and Developmental Biology. 8: 716. PMID 32850835 DOI: 10.3389/fcell.2020.00716 |
0.529 |
|
| 2020 |
O'Hara DM, Pawar G, Kalia SK, Kalia LV. LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson's Disease? Frontiers in Neuroscience. 14: 577. PMID 32625052 DOI: 10.3389/fnins.2020.00577 |
0.378 |
|
| 2020 |
Maclagan LC, Visanji NP, Cheng Y, Tadrous M, Lacoste AMB, Kalia LV, Bronskill SE, Marras C. Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. Pharmacoepidemiology and Drug Safety. PMID 32410265 DOI: 10.1002/Pds.5015 |
0.305 |
|
| 2020 |
O'Hara DM, Kalia SK, Kalia LV. Methods for detecting toxic α-synuclein species as a biomarker for Parkinson's disease. Critical Reviews in Clinical Laboratory Sciences. 1-17. PMID 32116096 DOI: 10.1080/10408363.2019.1711359 |
0.405 |
|
| 2020 |
Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. PMID 32102975 DOI: 10.1212/Wnl.0000000000009107 |
0.353 |
|
| 2020 |
McKinnon C, De Snoo ML, Gondard E, Neudorfer C, Chau H, Ngana SG, O'Hara DM, Brotchie JM, Koprich JB, Lozano AM, Kalia LV, Kalia SK. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein. Acta Neuropathologica Communications. 8: 17. PMID 32059750 DOI: 10.1186/s40478-020-0894-0 |
0.398 |
|
| 2018 |
Kalia LV. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid. Parkinsonism & Related Disorders. PMID 30466800 DOI: 10.1016/j.parkreldis.2018.11.016 |
0.332 |
|
| 2018 |
Hara DMO, Kalia SK, Kalia LV. Emerging Disease-Modifying Strategies Targeting α-Synuclein for the Treatment of Parkinson Disease. British Journal of Pharmacology. PMID 29722028 DOI: 10.1111/bph.14345 |
0.367 |
|
| 2017 |
Friesen EL, De Snoo ML, Rajendran L, Kalia LV, Kalia SK. Chaperone-Based Therapies for Disease Modification in Parkinson's Disease. Parkinson's Disease. 2017: 5015307. PMID 28913005 DOI: 10.1155/2017/5015307 |
0.376 |
|
| 2017 |
Koprich JB, Kalia LV, Brotchie JM. Animal models of α-synucleinopathy for Parkinson disease drug development. Nature Reviews. Neuroscience. PMID 28747776 DOI: 10.1038/nrn.2017.75 |
0.363 |
|
| 2017 |
Rosborough K, Patel N, Kalia LV. α-Synuclein and Parkinsonism: Updates and Future Perspectives. Current Neurology and Neuroscience Reports. 17: 31. PMID 28324300 DOI: 10.1007/s11910-017-0737-y |
0.375 |
|
| 2017 |
Breen DP, Kalia LV. Exploiting the aggregation properties of alpha-synuclein for diagnostic purposes. Movement Disorders : Official Journal of the Movement Disorder Society. 32: 106. PMID 27896833 DOI: 10.1002/mds.26884 |
0.503 |
|
| 2016 |
Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. Trends in Neurosciences. PMID 27776749 DOI: 10.1016/J.Tins.2016.09.003 |
0.409 |
|
| 2016 |
Rowland NC, Kalia SK, Kalia LV, Larson PS, Lim DA, Bankiewicz KS. Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. Molecular Therapy. Methods & Clinical Development. 3: 15051. PMID 26817024 DOI: 10.1038/Mtm.2015.51 |
0.333 |
|
| 2016 |
Kalia LV, Lang AE. Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. Nature Reviews. Neurology. 12: 65-6. PMID 26782330 DOI: 10.1038/nrneurol.2015.249 |
0.303 |
|
| 2015 |
Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1442-50. PMID 26208210 DOI: 10.1002/mds.26354 |
0.321 |
|
| 2015 |
Kalia LV, Kalia SK. α-Synuclein and Lewy pathology in Parkinson's disease. Current Opinion in Neurology. 28: 375-81. PMID 26110807 DOI: 10.1097/WCO.0000000000000215 |
0.395 |
|
| 2015 |
Kalia LV, Lang AE. Parkinson's disease. Lancet. PMID 25904081 DOI: 10.1016/S0140-6736(14)61393-3 |
0.358 |
|
| 2014 |
Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbestael E, Chia R, Ndukwe K, Ding J, Nalls MA, Olszewski M, et al. Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America. 111: 2626-31. PMID 24510904 DOI: 10.1073/Pnas.1318306111 |
0.314 |
|
| 2014 |
AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 6-23. PMID 24085420 DOI: 10.1007/s13311-013-0218-1 |
0.329 |
|
| 2013 |
Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Annals of Neurology. 73: 155-69. PMID 23225525 DOI: 10.1002/Ana.23746 |
0.583 |
|
| 2011 |
Kalia LV, Kalia SK, Chau H, Lozano AM, Hyman BT, McLean PJ. Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). Plos One. 6: e14695. PMID 21358815 DOI: 10.1371/Journal.Pone.0014695 |
0.581 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2013 |
Dimant H, Kalia SK, Kalia LV, Zhu LN, Kibuuka L, Ebrahimi-Fakhari D, McFarland NR, Fan Z, Hyman BT, McLean PJ. Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathologica Communications. 1: 6. PMID 24252244 DOI: 10.1186/2051-5960-1-6 |
0.298 |
|
| 2022 |
Meng Y, Pople CB, Huang Y, Jones RM, Ottoy J, Goubran M, Oliveira LM, Davidson B, Lawrence LSP, Lau AZ, Bethune A, Maralani P, Abrahao A, Hamani C, Hynynen K, ... ... Kalia LV, et al. Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance-Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 36089809 DOI: 10.1002/mds.29190 |
0.294 |
|
| 2022 |
Kalia LV. First trials test targeting of α-synuclein for Parkinson disease. Nature Reviews. Neurology. PMID 36151474 DOI: 10.1038/s41582-022-00726-6 |
0.294 |
|
| 2023 |
Bloem BR, Kalia LV. The Journal of Parkinson's Disease Takes the Open Road. Journal of Parkinson's Disease. 13: 1-2. PMID 36744347 DOI: 10.3233/JPD-229011 |
0.288 |
|
| 2023 |
Bhidayasiri R, Kalia LV, Bloem BR. Tackling Parkinson's Disease as a Global Challenge. Journal of Parkinson's Disease. 13: 1277-1280. PMID 38143374 DOI: 10.3233/JPD-239005 |
0.286 |
|
| 2023 |
McFarthing K, Bloem BR, Kalia LV. People with Parkinson's as Partners for the Journal of Parkinson's Disease. Journal of Parkinson's Disease. 13: 125-126. PMID 36911950 DOI: 10.3233/JPD-239000 |
0.285 |
|
| 2019 |
McKinnon C, Gros P, Lee DJ, Hamani C, Lozano AM, Kalia LV, Kalia SK. Deep brain stimulation: potential for neuroprotection. Annals of Clinical and Translational Neurology. 6: 174-185. PMID 30656196 DOI: 10.1002/Acn3.682 |
0.282 |
|
| 2018 |
Meng Y, Voisin MR, Suppiah S, Kalia SK, Kalia LV, Hamani C, Lipsman N. Is there a role for MR-guided focused ultrasound in Parkinson's disease? Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29476631 DOI: 10.1002/mds.27308 |
0.281 |
|
| 2020 |
Mukherjee T, Ramaglia V, Abdel-Nour M, Bianchi AA, Tsalikis J, Chau HN, Kalia SK, Kalia LV, Chen JJ, Arnoult D, Gommerman JL, Philpott DJ, Girardin SE. The eIF2α kinase HRI triggers the autophagic clearance of cytosolic protein aggregates. The Journal of Biological Chemistry. PMID 33168630 DOI: 10.1074/jbc.RA120.014415 |
0.278 |
|
| 2020 |
Mukherjee T, Ramaglia V, Abdel-Nour M, Bianchi AA, Tsalikis J, Chau HN, Kalia SK, Kalia LV, Chen JJ, Arnoult D, Gommerman JL, Philpott DJ, Girardin SE. The eIF2α kinase HRI triggers the autophagic clearance of cytosolic protein aggregates. The Journal of Biological Chemistry. 296: 100050. PMID 33410405 DOI: 10.1074/jbc.RA120.014415 |
0.278 |
|
| 2022 |
Kalia LV, Bloem BR. A New Chapter for the Journal of Parkinson's Disease. Journal of Parkinson's Disease. 12: 1365-1367. PMID 35811539 DOI: 10.3233/JPD-229004 |
0.277 |
|
| 2015 |
Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. Jama Neurology. 72: 100-5. PMID 25401511 DOI: 10.1001/Jamaneurol.2014.2704 |
0.276 |
|
| 2019 |
Kalia LV. Expert comment: "A case of missing pathology in a patient with LRRK2 Parkinson's disease". Parkinsonism & Related Disorders. PMID 31727562 DOI: 10.1016/j.parkreldis.2019.11.005 |
0.27 |
|
| 2023 |
Albanese F, Bloem BR, Kalia LV. Addressing the "Replication Crisis" in the Field of Parkinson's Disease. Journal of Parkinson's Disease. 13: 849-850. PMID 37694309 DOI: 10.3233/JPD-239002 |
0.261 |
|
| 2023 |
Bloem BR, Kalia LV. Kathrin Brockmann, Milan Zimmermann, and Dareia Roos, Recipients of The Parkinson Prize 2023. Journal of Parkinson's Disease. 13: 1273-1276. PMID 38143375 DOI: 10.3233/JPD-239006 |
0.258 |
|
| 2013 |
Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 131-44. PMID 23225267 DOI: 10.1002/mds.25273 |
0.256 |
|
| 2008 |
Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. The Lancet. Neurology. 7: 742-55. PMID 18635022 DOI: 10.1016/S1474-4422(08)70165-0 |
0.216 |
|
| 2023 |
Lang S, Vetkas A, Conner C, Kalia LV, Lozano AM, Kalia SK. Predictors of Future Deep Brain Stimulation Surgery in de novo Parkinson's Disease. Movement Disorders Clinical Practice. 10: 933-942. PMID 37332645 DOI: 10.1002/mdc3.13747 |
0.196 |
|
| 2018 |
Kalia LV. Biomarkers for cognitive dysfunction in Parkinson's disease. Parkinsonism & Related Disorders. 46: S19-S23. PMID 28781202 DOI: 10.1016/j.parkreldis.2017.07.023 |
0.189 |
|
| 2019 |
De Snoo ML, Friesen EL, Zhang YT, Earnshaw R, Dorval G, Kapadia M, O'Hara DM, Agapova V, Chau H, Pellerito O, Tang MY, Wang X, Schmitt-Ulms G, Durcan TM, Fon EA, ... Kalia LV, et al. Bcl-2-associated athanogene 5 (BAG5) regulates Parkin-dependent mitophagy and cell death. Cell Death & Disease. 10: 907. PMID 31787745 DOI: 10.1038/S41419-019-2132-X |
0.184 |
|
| 2022 |
Huang Y, Meng Y, Pople CB, Bethune A, Jones RM, Abrahao A, Hamani C, Kalia SK, Kalia LV, Lipsman N, Hynynen K. Cavitation Feedback Control of Focused Ultrasound Blood-Brain Barrier Opening for Drug Delivery in Patients with Parkinson's Disease. Pharmaceutics. 14. PMID 36559101 DOI: 10.3390/pharmaceutics14122607 |
0.183 |
|
| 2021 |
Bloem BR, Trenkwalder C, Sanchez-Ferro A, Kalia LV, Alcalay R, Chiang HL, Kang UJ, Goetz C, Brundin P, Papa SM. COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel? Journal of Parkinson's Disease. PMID 33523021 DOI: 10.3233/JPD-212573 |
0.178 |
|
| 2017 |
Park S, Bin NR, Yu B, Wong R, Sitarska E, Sugita K, Ma K, Xu J, Tien CW, Algouneh A, Turlova E, Wang S, Siriya P, Shahid W, Kalia L, et al. UNC-18 and Tomosyn antagonistically control synaptic vesicle priming downstream of UNC-13 in C. elegans. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28821673 DOI: 10.1523/Jneurosci.0338-17.2017 |
0.157 |
|
| 2020 |
Meng Y, Pople CB, Kalia SK, Kalia LV, Davidson B, Bigioni L, Li DZ, Suppiah S, Mithani K, Scantlebury N, Schwartz ML, Hamani C, Lipsman N. Cost-effectiveness analysis of MR-guided focused ultrasound thalamotomy for tremor-dominant Parkinson's disease. Journal of Neurosurgery. 1-6. PMID 32764177 DOI: 10.3171/2020.5.JNS20692 |
0.153 |
|
| 2024 |
Outeiro TF, Kalia LV, Bezard E, Ferrario J, Lin CH, Salama M, Standaert DG, Taiwo L, Takahashi R, Vila M, Mollenhauer B, Svenningsson P. Basic Science in Movement Disorders: Fueling the Engine of Translation into Clinical Practice. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 38576081 DOI: 10.1002/mds.29802 |
0.152 |
|
| 2002 |
Pelkey KA, Askalan R, Paul S, Kalia LV, Nguyen TH, Pitcher GM, Salter MW, Lombroso PJ. Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. Neuron. 34: 127-38. PMID 11931747 DOI: 10.1016/S0896-6273(02)00633-5 |
0.13 |
|
| 2021 |
Oliveira LM, Rastin T, Nimmo GAM, Ross JP, Dion PA, Zhang M, Nevay DL, Arkadir D, Gotkine M, Barnett C, Shoesmith CL, Zimran A, Rogaeva EA, Zinman L, Rouleau GA, ... ... Kalia LV, et al. Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease. Neurology. Genetics. 7: e600. PMID 34017912 DOI: 10.1212/NXG.0000000000000600 |
0.128 |
|
| 2004 |
Kalia LV, Gingrich JR, Salter MW. Src in synaptic transmission and plasticity. Oncogene. 23: 8007-16. PMID 15489918 DOI: 10.1038/sj.onc.1208158 |
0.127 |
|
| 2022 |
Bloem BR, Kalia LV. Thomas G. Beach, MD, PhD, FRCPC, Charles H. Adler, MD, PhD, FAAN, and Simon Stott, PhD, recipients of the Parkinson Prize 2022. Journal of Parkinson's Disease. 12: 2283-2286. PMID 36565068 DOI: 10.3233/JPD-229010 |
0.126 |
|
| 2018 |
Picillo M, Lizarraga KJ, Friesen EL, Chau H, Zhang M, Sato C, Rooke G, Munhoz RP, Rogaeva E, Fraser PE, Kalia SK, Kalia LV. Parkinsonism due to A53E α-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30423204 DOI: 10.1002/Mds.27506 |
0.125 |
|
| 2020 |
Fomenko A, Lee DJ, McKinnon C, Lee EJ, de Snoo ML, Gondard E, Neudorfer C, Hamani C, Lozano AM, Kalia LV, Kalia SK. Deep Brain Stimulation of the Medial Septal Nucleus Induces Expression of a Virally Delivered Reporter Gene in Dentate Gyrus. Frontiers in Neuroscience. 14: 463. PMID 32477058 DOI: 10.3389/Fnins.2020.00463 |
0.12 |
|
| 2024 |
Gros P, Spee BTM, Bloem BR, Kalia LV. If Art Were a Drug: Implications for Parkinson's Disease. Journal of Parkinson's Disease. PMID 38788090 DOI: 10.3233/JPD-240031 |
0.12 |
|
| 2024 |
Kalia LV, Bloem BR. Sharing Advice that We Give to People with Parkinson's Disease. Journal of Parkinson's Disease. 14: 361-362. PMID 38669485 DOI: 10.3233/JPD-249003 |
0.12 |
|
| 2024 |
Davidson B, Milosevic L, Kondrataviciute L, Kalia LV, Kalia SK. Neuroscience fundamentals relevant to neuromodulation: Neurobiology of deep brain stimulation in Parkinson's disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 21: e00348. PMID 38579455 DOI: 10.1016/j.neurot.2024.e00348 |
0.12 |
|
| 2024 |
Schneider RB, Phillips O, Kalia L. Conventionvs. Innovation I: Digital technology will replace clinic-based care in Parkinson disease. Parkinsonism & Related Disorders. 106067. PMID 38443214 DOI: 10.1016/j.parkreldis.2024.106067 |
0.12 |
|
| 2006 |
Kalia LV, Pitcher GM, Pelkey KA, Salter MW. PSD-95 is a negative regulator of the tyrosine kinase Src in the NMDA receptor complex. The Embo Journal. 25: 4971-82. PMID 16990796 DOI: 10.1038/sj.emboj.7601342 |
0.117 |
|
| 2003 |
Kalia LV, Salter MW. Interactions between Src family protein tyrosine kinases and PSD-95. Neuropharmacology. 45: 720-8. PMID 14529711 DOI: 10.1016/S0028-3908(03)00313-7 |
0.113 |
|
| 2023 |
Kalia LV, Nimmo GAM, Mestre TA. Genetic Testing in Clinical Movement Disorders: A Case-Based Review. Seminars in Neurology. PMID 36854393 DOI: 10.1055/s-0043-1763507 |
0.112 |
|
| 2009 |
Ng D, Pitcher GM, Szilard RK, Sertié A, Kanisek M, Clapcote SJ, Lipina T, Kalia LV, Joo D, McKerlie C, Cortez M, Roder JC, Salter MW, McInnes RR. Neto1 is a novel CUB-domain NMDA receptor-interacting protein required for synaptic plasticity and learning. Plos Biology. 7: e41. PMID 19243221 DOI: 10.1371/Journal.Pbio.1000041 |
0.101 |
|
| 2019 |
Kalia LV, Jellinger KA. Multiple system atrophy and myoclonus: A morphologic marker in the spinal cord? Neurology. 93: 287-288. PMID 31405931 DOI: 10.1212/Wnl.0000000000007941 |
0.099 |
|
| 2021 |
Saranza G, Chen KS, Ganos C, Kalia LV, Chen R, Lang AE. Botulinum toxin-associated prolonged remission of idiopathic cervical dystonia. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 1-16. PMID 33397526 DOI: 10.1017/cjn.2020.280 |
0.09 |
|
| 2003 |
Fam SR, Gallagher CJ, Kalia LV, Salter MW. Differential frequency dependence of P2Y1- and P2Y2- mediated Ca 2+ signaling in astrocytes. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 4437-44. PMID 12805284 DOI: 10.1523/Jneurosci.23-11-04437.2003 |
0.089 |
|
| 2004 |
Salter MW, Kalia LV. Src kinases: a hub for NMDA receptor regulation. Nature Reviews. Neuroscience. 5: 317-28. PMID 15034556 DOI: 10.1038/nrn1368 |
0.079 |
|
| 2003 |
Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT, Salter MW. Glycine binding primes NMDA receptor internalization. Nature. 422: 302-7. PMID 12646920 DOI: 10.1038/Nature01497 |
0.074 |
|
| 2022 |
Fereshtehnejad SM, Saleh PA, Oliveira LM, Patel N, Bhowmick S, Saranza G, Kalia LV. Movement disorders in hereditary spastic paraplegia (HSP): a systematic review and individual participant data meta-analysis. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. PMID 36441344 DOI: 10.1007/s10072-022-06516-8 |
0.073 |
|
| 2011 |
Pitcher GM, Kalia LV, Ng D, Goodfellow NM, Yee KT, Lambe EK, Salter MW. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nature Medicine. 17: 470-8. PMID 21441918 DOI: 10.1038/Nm.2315 |
0.067 |
|
| 2019 |
Rajalingam R, Breen DP, Chen R, Fox S, Kalia LV, Munhoz RP, Slow E, Strafella AP, Lang AE, Fasano A. The clinical significance of lower limb tremors. Parkinsonism & Related Disorders. PMID 31201091 DOI: 10.1016/J.Parkreldis.2019.06.007 |
0.054 |
|
| 2003 |
Kalia LV. Barriers to women clinician-scientists: a trainee's perspective. Clinical and Investigative Medicine. Medecine Clinique Et Experimentale. 26: 15-6. PMID 12659464 |
0.054 |
|
| 2022 |
Sáenz-Farret M, Lang AE, Kalia L, Cunha I, Sousa M, Kuhlman G, Ganos C, Munhoz RP, Fasano A, Piña-Avilés CE, Zúñiga-Ramírez C. Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia. Movement Disorders Clinical Practice. 9: 522-529. PMID 35586535 DOI: 10.1002/mdc3.13437 |
0.05 |
|
| 2021 |
Kapadia M, De Snoo ML, Kalia LV, Kalia SK. Regulation of Parkin-dependent mitophagy by Bcl-2-associated athanogene (BAG) family members. Neural Regeneration Research. 16: 684-685. PMID 33063725 DOI: 10.4103/1673-5374.295330 |
0.045 |
|
| 2013 |
Civardi C, Collini A, Kalia LV, Lang AE, Aviv RI, Masellis M. Hemichorea-hemiballism associated with hyperglycemia and a developmental venous anomaly. Neurology. 81: 1181. PMID 24062343 DOI: 10.1212/Wnl.0B013E3182A7A945 |
0.043 |
|
| 2017 |
Baskin B, Kalia LV, Banwell BL, Ray PN, Yoon G. Complex genomic rearrangement in SPG11 due to a DNA replication-based mechanism. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29082553 DOI: 10.1002/mds.27188 |
0.042 |
|
| 2018 |
Coakeley S, Ang LC, Jansen GH, Cho SS, Lang AE, Houle S, Kalia LV, Strafella AP. [ F]AV-1451 binding and postmortem pathology of CBD. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30136331 DOI: 10.1002/mds.27356 |
0.041 |
|
| 2014 |
Kalia LV, Rockman-Greenberg C, Borys A, Lang AE. Tremor in Spinocerebellar Ataxia Type 12. Movement Disorders Clinical Practice. 1: 76-78. PMID 30363887 DOI: 10.1002/mdc3.12015 |
0.025 |
|
| 2005 |
Kalia LV, O'Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England). 11: 322-7. PMID 15957515 DOI: 10.1191/1352458505ms1168oa |
0.017 |
|
| 2021 |
Day LB, Rajendram P, Kalia LV, Gold WL. AN INTELLIGENT DIAGNOSIS: SMART SYNDROME. The American Journal of Medicine. PMID 33444593 DOI: 10.1016/j.amjmed.2020.11.034 |
0.01 |
|
| 2013 |
Kalia LV, Lang AE, Aviv RI, Masellis M. Author response. Neurology. 81: 1181. PMID 24191352 DOI: 10.1212/WNL.0b013e3182a7a945 |
0.01 |
|
| 2010 |
Kalia LV, Lee L, Kalia SK, Pirouzmand F, Rapoport MJ, Aviv RI, Mozeg D, Symons SP. Thoracic myelopathy from coincident fluorosis and epidural lipomatosis Canadian Journal of Neurological Sciences. 37: 276-278. PMID 20437944 |
0.01 |
|
| Hide low-probability matches. |